Cardio-oncology & otherGuideline or statement
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
- Scientific statement
Scope
As issued by the authors
CV toxicities of immune therapies for cancer (ICI, CAR-T, natural killer (NK) and TIL therapies): pathophysiology, epidemiology, diagnosis and management; gaps in the literature and future research
Original publication
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. Published 1 August 2024. doi:10.1002/ejhf.3340
Summarised from the published abstract; every number is checked against it